Navigation Links
The Hemostemix Group of Companies Provides Corporate Strategy Update

Toronto, Ontario (PRWEB) May 31, 2013

The Hemostemix Group of Companies released an update today available to shareholders and potential investors outlining key elements of its strategic plan for the upcoming year.

The Hemostemix Group is comprised of HemoStemix Ltd. (HemoStemix), a company incorporated in Israel with an operating research, development and manufacturing facility in Ness Ziona, Kwalata Trading Ltd. (“Kwalata”), registered in Cyprus, and the parent company Theravitae, Inc. (“TVI”) based in Toronto, Ontario, Canada (collectively the “Hemostemix Group” or “Group”).


On May 14, Technical Ventures RX Corp. (TSX-V:TIK.P) announced a letter of intent signed with TVI regarding a proposed Qualifying Transaction in which TIK.P would acquire TVI in a share exchange. For a copy of the press release, see


TVI has also announced that it has engaged Wolverton Securities Ltd. as agent for a private placement, on a commercially reasonable efforts basis, for minimum gross proceeds of $1 million.


The Hemostemix Group has identified several sources of non-dilutive grant or match funding that it intends to pursue in the near-term for projects which are critical to expediting the company’s commercialization strategy.

Clinical Trial

The Group has completed three clinical trials to-date, the data from which were submitted last year to Health Canada and which formed the basis for its recent clearance to proceed with a phase 2 clinical trial in Canada for the treatment of critical limb ischemia. That trial is expected to start later this year.

Research & Development

Recently the Group also announced that a Letter of Intent has been signed with the Austrian-based Ludwig Boltzmann Institute for Experimental and Clinical Traumatology (“LBI”) to collaborate in performing experiments to assess various clinical applications for Hemostemix’ technology as well as other potential mutually beneficial projects. The LBI is an organization dedicated to research in the fields of tissue engineering, stem cells and regenerative medicine For more information on LBI, see


The company continues to aggressively file and maintain a global patent portfolio covering a broad technology platform now protected by 37 patents issued in major markets. The Hemostemix Group is also actively identifying and engaging in early-stage discussions pertaining to potential commercial licenses, joint-ventures, and other types of strategic collaborations.

About HemoStemix Ltd.

HemoStemix Ltd. is a company incorporated in Israel with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. HemoStemix and Kwalata Trading Ltd. (“Kwalata”), registered in Cyprus, are wholly-owned subsidiaries of Canadian-based parent company TVI (together the “Hemostemix Group”). Kwalata holds the intellectual property on behalf of the Hemostemix Group.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
2. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
3. Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group
4. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5. MZ Group to Sponsor Asia BiotechInvest 2013 Conference
6. DTx Partners with Caxiam Group for Redesign
7. Jackson Hole Group, LLC Welcomes Marnie McBryde as a New Principal
8. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy
9. Cellular Biomedicine Group Provides Update and 2013 Milestones
10. Oncotest GmbH and Debiopharm Group Announce a Successful Partnership in the Identification of Biomarker Candidates
11. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
Post Your Comments:
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
(Date:6/23/2016)... June 23, 2016 ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... . The Global Cell ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: ) ... their customers enhanced security to access and transact ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):